<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75482">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01822444</url>
  </required_header>
  <id_info>
    <org_study_id>ICORG 12-16</org_study_id>
    <nct_id>NCT01822444</nct_id>
  </id_info>
  <brief_title>ANGIOPREDICT. ICORG 12-16, V3</brief_title>
  <official_title>Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICORG- All Ireland Cooperative Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICORG- All Ireland Cooperative Oncology Research Group</source>
  <oversight_info>
    <authority>Ireland: Health Information and Quality Authority</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      The primary objective is to validate previously identified predictive/prognostic genomic DNA
      and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced
      CRC (a CRC) or metastatic CRC (mCRC).

      Secondary Objective:

        1. To test the efficacy of bvz in combination with FOLFOX in patients with newly diagnosed
           advanced or metastatic K-ras mutant CRC and

        2. To determine the progression free and overall survival of patients under first line
           FOLFOX + bvz in aCRC or mCRC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Type of Study: Exploratory, translational, multicenter and multinational Phase II study.

      Patient Population:All patients from the intent-to-treat population with aCRC or mCRC,
      (incurable with any conventional multimodality approach) and who fulfil all inclusion and
      exclusion criteria.

      Number of Patients: 224

      Sample Type:

      Serial tissue and blood samples will be collected before (week 0), during (week 6, month 3
      and 6) and at the end of treatment (month 12).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Identification of biomarkers</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identification of biomarkers, which are predictive for response and/or prolonged PFS to FOLFOX/bvz combination therapy in aCRC or mCRC patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of identified biomarkers</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validation of identified biomarkers with regard to response rate/failure to further treatment strategy, PFS, overall survival (OS) and toxicity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Intent-to-treat population with aCRC or mCRC</arm_group_label>
    <description>Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker analysis</intervention_name>
    <arm_group_label>Intent-to-treat population with aCRC or mCRC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients from the intent-to-treat population with aCRC or mCRC, (incurable with any
        conventional multimodality approach) and who fulfil all inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years of age.

          2. Patients diagnosed with recurrent or de novo, locally advanced (unresectable) or
             metastatic adenocarcinoma of the colon or rectum.

          3. Planned combination bevacizumab (bvz) treatment with either:

               -  leucovorin, fluorouracil and oxaliplatin (FOLFOX)

               -  capecitabine and oxaliplatin (XELOX)

               -  leucovorin, fluorouracil and irinotecan (FOLFIRI)

               -  capecitabine and irinotecan (XELIRI)

          4. Naive for bvz

          5. An evaluable site of disease

          6. ECOG Performance status 0, 1, or 2

          7. Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN or GFR ≥ 50ml/min

          8. Adequate hematopoietic function [white blood cell (WBC) count ≥ 3000/μl, absolute
             neutrophil count (ANC) ≥1500/μl, platelets ≥100 000/μl, haemoglobin level ≥ 9.0 g/dl]

          9. Adequate end organ function, defined as the following: total bilirubin &lt; 1.5 x ULN,
             SGOT and SGPT &lt; 3.0 x ULN (in case of liver metastases SGOT and SGPT &lt; 5.0 x ULN)

         10. Ability to give signed informed consent prior to any screening procedures

         11. FFPE Tissue is available

        Exclusion Criteria:

          1. Patient has received any other investigational product within 28 days of first day of
             study drug dosing

          2. Patients having familial and/or hereditary CRC

          3. CRC associated with ulcerative colitis

          4. Patient with any significant history of non-compliance to medical regimens or with
             inability to grant reliable informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01 2214000</phone>
    </contact>
    <investigator>
      <last_name>Ray McDermott, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact person</last_name>
      <phone>01 4142000</phone>
    </contact>
    <investigator>
      <last_name>Ray McDermott, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01 4103000</phone>
    </contact>
    <investigator>
      <last_name>John Kennedy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sligo General Hospital</name>
      <address>
        <city>Sligo</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Martin, Dr</last_name>
      <phone>071-9171111</phone>
    </contact>
    <investigator>
      <last_name>Michael martin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Advanced Colorectal Cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Locally Advanced Colorectal Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
